Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 513 followers
Latest posts
Last updated 4 days ago
Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
4 days ago
Application based on data from positive GLISTEN phase III trial
GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio
7 days ago
GSK today announced that data across the oncology pipeline and portfolio will...
PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee
8 days ago
Data to be part of a planned US FDA filing in H2...
Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma
13 days ago
Positive opinion supported by superior efficacy shown in two head-to-head phase III...
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
14 days ago
Approval based on the positive MATINEE and METREX phase III trials
Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple myeloma
18 days ago
Second major approval for Blenrep combinations, with more expected in 2025
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
23 days ago
Affecting up to 5% of the global population, SLD represents an area...
GSK provides update on belrestotug development programme
23 days ago
GSK with its development partner iTeos Therapeutics, Inc., has confirmed it is...
GLISTEN phase III trial results show linerixibat significantly improves cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)
28 days ago
Late-breaking results presented at the European Association for the Study of the...
GSK continues to advance the future of respiratory medicine and patient care with new data at ATS
about 1 month ago
40+ abstracts across GSK’s inhaled and respiratory biologics portfolio
Nucala (mepolizumab) delivers clinically meaningful and statistically significant reduction in COPD exacerbations, with positive MATINEE trial results published in New England Journal of Medicine
about 1 month ago
21% reduction in annualised rate of moderate/severe exacerbations in a wide COPD...
GSK makes strong start to 2025 with growth in sales, profits and earnings
about 1 month ago
Q1 2025 performance highlights